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were required for DRUG to generate greater gains than FBT. The incremental cost 
of moving from the lowest cost strategy to FBT with the greatest gain was $507 
per additional QALY gained. CONCLUSIONS: All treatment strategies examined 
for urge incontinence provide clinical benefits, are relatively cost effective and 
offer QALYs at a bargain price. Clinicians should be encouraged to screen for and 
actively offer treatment options for urge incontinence in older adults.  
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OBJECTIVES: To assess the cost-effectiveness analyses for refractory overactive 
bladder (OAB). METHODS: A systematic literature review of economic 
evaluations of therapies for OAB was conducted using PubMed. For inclusion, 
studies had to compare two or more OAB treatments including at least one third-
line treatment according to the American Urological Association. Articles were 
excluded if the study population was classified as neurogenic or predominantly 
stress incontinence. RESULTS: The initial search yielded 654 articles. After title 
review, 92 abstracts were identified as potentially eligible articles. Sixty-five 
abstracts were excluded because they did not meet inclusion criteria. Twenty-
seven full-text articles were evaluated, of which 19 studies were excluded for 
lack of third-line treatment and two studies were excluded because OAB was 
classified as neurogenic. Of the six included studies, five were decision models, 
and one was a prospective cohort. Three of the decision models compared 
onabotulinumtoxin A to sacral nerve modulation with one of the models also 
allowing continued anticholinergic use as an additional intervention. One 
decision model compared onabotulinumtoxin A to anticholinergics. The 
remaining decision model compared peripheral tibial nerve stimulation to 
extended-release tolterodine. All of the studies were published recently, between 
2009 and 2011. In four of the studies the perspective was “societal,” and in the 
remaining two it was from the perspectives of government payers. All decision 
analyses were based on direct medical costs and did not include the cost of lost 
productivity. Most of the studies based costs and utility scores on women with 
stress incontinence, not patients with refractory urge incontinence. No studies 
used direct comparative data or long-term evidence from clinical studies to 
evaluate refractory treatments. CONCLUSIONS: Few published economic 
evaluations exist that assess treatments for refractory OAB. Additional studies 
on the effectiveness of refractory OAB treatments are needed to accurately 
assess the cost-effectiveness of these interventions.  
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OBJECTIVES: To evaluate long-term cost-effectiveness of a fixed-dose 
combination (FDC) product comprising 0.5mg dutasteride and 0.4mg tamsulosin 
daily, compared to concomitant administration of both dutasteride (0.5 mg)  
and tamsulosin (0.4 mg) monotherapies for the treatment of symptomatic benign 
prostatic hyperplasia (BPH) in Quebec, Canada. METHODS: Our previously 
reported Markov state transition model was adapted to simulate the costs  
and outcomes associated with patients on either type of combination therapy for 
a 10-year period. As both combination therapies have been shown to be 
bioequivalent, a cost-minimization analysis was conducted from the perspective 
of the Quebec provincial health care system. The model follows a Quebec cohort 
of 312,448 male patients aged ≥50 years, diagnosed with moderate to severe 
symptomatic BPH, similar to the cohort studied in the pivotal 4-year CombAT 
study, which evaluated concomitant therapy of dutasteride and tamsulosin  
in BPH patients at risk of clinical progression. Costs and outcomes  
were discounted at 5% per year. Results are presented in the form of total health 
care costs, including dispensing fees, over a period of 10 years for  
both combination therapies. RESULTS: Over a 10-year period, the use of  
FDC compared with concomitant Dutasteride + Tamsulosin therapy could  
save the Quebec health care payer up to $356.86m over 10 years ($1.995bn for 
FDC vs $2.352bn for concomitant therapy, or $1152/patient) when dispensing fees 
were included, or $140.4m (or $450/patient) without dispensing fees. This cost-
saving is driven by lower wholesale acquisition costs of FDC compared to 
Dutasteride + Tamsulosin administered concomitantly, and the fact that that 
only one prescription is needed when dispensing the new FDC (when 
considering dispensing fees). CONCLUSIONS: The introduction of the FDC in 
Quebec for the treatment of moderate to severe symptomatic BPH patients 
would be expected to yield a cost-savings to the health care system over a 10-
year period.  
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OBJECTIVES: To compare health care costs and utilizations between patients 
with an overactive bladder (OAB) who were adherent to OAB medication versus 
those who were not. METHODS: Adult patients with at least two OAB diagnoses 
and two consecutive OAB prescriptions (tolterodine tartrate, oxybutynin 
chloride/transdermal, trospium chloride, solifenacin succinate, darifenacin 
hydrobromide) between July 1, 2007-December 31, 2010 were selected from the 
MarketScan Commercial and Medicare Supplemental Claims Database. 
Continuous eligibility for 6 months pre- and 12 months post-index date (first 
OAB prescription date), and no prior use of OAB medications during the 6-month 
baseline were required. Adherent (proportion of days covered [PDC] to 
medication ≥0.8) and non-adherent (PDC<0.8) cohorts were defined. Follow-up 
health care costs and utilizations were compared between the cohorts. 
Propensity score matching was used to control baseline differences in age, 
gender, region, comorbidities, costs and utilizations. RESULTS: A total of 45,856 
patients were identified (adherent: N=11,851; non-adherent: N=34,005). Adherent 
patients were older (65.40 vs. 62.50, p<0.0001), more likely to be male (34.01% vs. 
30.59%, p<0.0001), and had higher Charlson Comorbidity Index scores (1.34 vs. 
1.24, p<0.0001). During 1-year follow-up, adherent patients had lower inpatient 
(17.00% vs. 21.32%) and emergency room (ER) visit rates (27.12% vs. 32.21%), lower 
medical costs ($22,608 vs. $26,000), but higher pharmacy costs ($12,382 vs. $7,526) 
than non-adherent patients (all p-values<0.0001). After matching, 11,850 patients 
from each cohort were further analyzed. Adjusted outcomes revealed that 
adherent patients had lower inpatient (17.00% vs. 23.99%) and ER visit rates 
(27.11% vs. 34.24%), translating to lower inpatient costs ($6,453 vs. $9,187, 
p<0.0001). Higher pharmacy costs for adherent patients (all-cause: $12,374 vs. 
$9,011; OAB-related: $2,238 vs. $945, all p<0.0001) were offset by lower medical 
costs (all-cause: $22,553 vs. $27,985; OAB-related: $732 vs. $1,289, all p<0.0001). 
CONCLUSIONS: Higher adherence with OAB medications was associated with 
fewer inpatient and ER visits, higher pharmacy costs, but significant lower 
medical and total costs.  
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OBJECTIVES: Few utility data are available for overactive bladder (OAB) in the 
literature. This study compared utilities derived from a disease-specific 
instrument, OAB-5D, and a generic instrument, EQ-5D, according to severity of 
OAB symptoms and evaluated their sensitivity to change. METHODS: Analyses 
were based on pooled data from three 12-week randomized controlled trials of 
OAB treatments. EQ-5D and OAB-5D were assessed monthly. Time trade-off 
tariffs elicited from UK population were applied to obtain utilities from both 
instruments. Repeated measures linear regression was used to estimate 
differences between EQ-5D and OAB-5D utilities by symptom severity level for 
micturition frequency and incontinence. Variations in utility from baseline to 
week 12 were estimated by symptomatic response (improvement, stable or 
worsening). RESULTS: The sample included 4349 OAB patients. Mean utilities 
were 0.82 (standard deviation: ±0.21) for EQ-5D and 0.86 (±0.09) for OAB-5D.  
The correlation between the two measures was 0.33 (p<0.0001). EQ-5D and OAB-
5D utilities increased as OAB symptoms improved. Utilities were similar between 
instruments for patients with severe symptoms, but OAB-5D utilities  
were significantly greater than EQ-5D utilities for mild cases. Incontinence  
had more impact on both OAB-5D and EQ-5D utilities than micturition 
frequency. Changes from baseline in OAB-5D utility differed significantly 
according to symptomatic response. Changes in EQ-5D utility were not 
significantly associated with changes in micturition frequency and weakly 
associated with changes in incontinence severity among patients with mild 
symptoms at baseline. CONCLUSIONS: This study suggests that EQ-5D and OAB-
5D are sensitive tools to measure differences in efficacy between OAB 
treatments, especially in severe cases. However, EQ-5D may not be as sensitive 
as OAB-5D in measuring differences between treatments in milder cases. A 
limitation of OAB-5D may be that it over estimates utilities in less severe cases 
since it does not capture effects of co-morbidities on health-related quality of 
life.  
 
PUK15  
RESULTS OF A STUDY EVALUATING PATIENT'S PERCEPTION  
REGARDING THEIR ERYTHROPOIESIS STIMULATING AGENT TREATMENT IN  
CHRONIC KIDNEY DISEASE USING A CHOICE BASED CONJOINT  
ANALYSIS  
Pau D1, Choukroun G2, Moranne O3, Vigneau C4, Isnard-Bagnis C5, Boutry X6, Gokou S1, 
Rouanet S1, Triglia A1 
1Roche, Boulogne-Billancourt, France, 2CHU Amiens, Amiens, France, 3Hôpital Pasteur, Nice, 
France, 4Hôpital Pontchaillou, Rennes, France, 5AP-HP Pitié-Salpêtrière, Paris, France, 6Axess 
Research, Champagne au Mont d'Or, France  
OBJECTIVES: Patient’s perception regarding their treatment has a real interest in 
health care, especially in chronic disease. The Percepolis study aims to describe 
patient’s preference regarding their ESA treatment. METHODS: This is a 6-month 
multicenter prospective Non-Interventional Study conducted by 111 French 
nephrologists in 2011. Eligible patients were patients not on dialysis, ESA naïve 
or not at baseline. The primary endpoint was the relative importance according 
